Navigation Links
WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
Date:8/22/2008

SHANGHAI, China, Aug. 22 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has promoted Dr. Rujian Ma to Vice President of Synthetic Chemistry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Ma will report directly to Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

"I am very delighted to promote Dr. Ma to this new leadership position. Dr. Ma's depth of synthetic chemistry experience and his commitment and coaching capabilities of our young scientists undoubtedly will further accelerate the development of our core synthetic chemistry division. His new assignment will also help us continually improve our service quality and productivity and to serve our customers better." commented Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

Dr. Ma received his Ph.D. in Organic Chemistry from the University of Tokushima, Japan and joined in WuXi in March 2001.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
2. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
3. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
4. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
5. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
6. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
7. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
8. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
9. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
10. WuXi PharmaTech Announces First Quarter 2008 Results
11. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2019)... ... August 07, 2019 , ... Locus Agricultural Solutions (Locus AG) reports record levels ... “probiotics”), including Rhizolizer ® , which is pulling up to 121% more carbon ... offered to date. Results from the treatment of almonds, cherries, turf/sod, grapes and citrus ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... Edwardsville for the launch of a community project that will engage middle and ... supports the project, entitled “A Youth-Led Citizen Science Network for Community Environmental Assessment.” ...
(Date:7/23/2019)... ... 22, 2019 , ... While today Visikol is primarily focused ... 3D tissue imaging , digital pathology , 3D cell culture ... as a products company. These products are focused on addressing the limitations associated ...
(Date:7/17/2019)... SOMERSET, N.J. (PRWEB) , ... ... ... today announced a long-term strategic agreement for the development and manufacturing of ... (SMA). , Through this collaboration, AveXis, a Novartis company, will have dedicated ...
Breaking Biology Technology:
(Date:8/19/2019)... ... August 19, 2019 , ... ... through the use of ultra-thin two dimensional slices which are placed on microscope ... limited for complex tissues and complicated features such as vasculature and thus researchers ...
(Date:8/15/2019)... ... August 15, 2019 , ... Make IVD ... of routine tasks. That was the message at the world's largest gathering of ... The American Association for Clinical Chemistry (AACC) Annual Scientific Meeting was held in ...
(Date:8/14/2019)... ... ... Join Jonathan Riek, PhD, VP, Musculoskeletal & Metabolic Imaging, BioTel Research ... to learn about two common imaging methods in NAFLD/NASH to aid with early disease ... liver disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided into ...
Breaking Biology News(10 mins):